Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Literature DB >> 11577256

Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Abstract

Plasminogen activator inhibitor type-1 (PAI-1) is a rapid inhibitor of tissue plasminogen activator (tPA) in circulation. Evidence suggests that the PAI-1 concentration is responsible for the regulation of the endogenous fibrinolytic system through its tPA/PAI-1 interactions. Accordingly, increased levels of PAI-1 have emerged as a masker for an increased thrombolic risk. This article represents a status report of mechanism of action, regulation of plasma levels, as well as the role of PAI-1 in arterial and venous thromboembolic disease.

Entities: Disease Gene

Mesh：

Substances：

Year: 2001 PMID： 11577256 DOI： 10.1023/a:1011955018052

Source DB: PubMed Journal: J Thromb Thrombolysis ISSN： 0929-5305 Impact factor: 2.300

166 in total

Review 1. The adipocyte and hemostatic balance in obesity: studies of PAI-1.

Authors: D J Loskutoff; F Samad
Journal: Arterioscler Thromb Vasc Biol Date: 1998-01 Impact factor: 8.311

2. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.

Authors: I Shimomura; T Funahashi; M Takahashi; K Maeda; K Kotani; T Nakamura; S Yamashita; M Miura; Y Fukuda; K Takemura; K Tokunaga; Y Matsuzawa
Journal: Nat Med Date: 1996-07 Impact factor: 53.440

3. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients.

Authors: P J Grant; M H Stickland; N A Booth; C R Prentice
Journal: Diabet Med Date: 1991-05 Impact factor: 4.359

4. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.

Authors: P E Morange; M C Alessi; M Verdier; D Casanova; G Magalon; I Juhan-Vague
Journal: Arterioscler Thromb Vasc Biol Date: 1999-05 Impact factor: 8.311

5. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression.

Authors: H C Chen; J L Bouchie; A S Perez; A C Clermont; S Izumo; J Hampe; E P Feener
Journal: Arterioscler Thromb Vasc Biol Date: 2000-10 Impact factor: 8.311

6. Dietary regulation of fibrinolytic factors.

Authors: M Mehrabian; J B Peter; R J Barnard; A J Lusis
Journal: Atherosclerosis Date: 1990-09 Impact factor: 5.162

7. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

Authors: A M Thögersen; J H Jansson; K Boman; T K Nilsson; L Weinehall; F Huhtasaari; G Hallmans
Journal: Circulation Date: 1998-11-24 Impact factor: 29.690

8. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.

Authors: K Huber; D Rosc; I Resch; E Schuster; D H Glogar; F Kaindl; B R Binder
Journal: Thromb Haemost Date: 1988-12-22 Impact factor: 5.249

9. [Persistent changes in tissue-type plasminogen activator and plasminogen activator inhibitor fibrinolytic parameters in patients following juvenile ischemic cerebral infarct].

Authors: C Baumgartner; K Huber; F Holzner; K Zeiler; E Auff; B R Binder
Journal: Klin Wochenschr Date: 1988-11-15

10. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.

Authors: K W Klinger; R Winqvist; A Riccio; P A Andreasen; R Sartorio; L S Nielsen; N Stuart; P Stanislovitis; P Watkins; R Douglas
Journal: Proc Natl Acad Sci U S A Date: 1987-12 Impact factor: 11.205

19 in total

Review 1. Impaired fibrinolysis in the antiphospholipid syndrome.

Authors: Katie A Krone; Kristi L Allen; Keith R McCrae
Journal: Curr Rheumatol Rep Date: 2010-02 Impact factor: 4.592

2. Thrombin-thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis.

Authors: A V Iakhiaev; A Nalian; K Koenig; S Idell
Journal: Thromb Res Date: 2007-02-02 Impact factor: 3.944

3. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting.

Authors: R Marcucci; D Brogi; F Sofi; C Giglioli; S Valente; A Alessandrello Liotta; M Lenti; A M Gori; D Prisco; R Abbate; G F Gensini
Journal: Heart Date: 2005-07-01 Impact factor: 5.994

4. Plasminogen activator inhibitor-1 polymorphisms (-844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables.

Authors: Jorge Ramón Padilla-Gutiérrez; Claudia Azucena Palafox-Sánchez; Yeminia Valle; Gerardo Orozco-Barocio; Edith Oregón-Romero; Mónica Vázquez-Del Mercado; Héctor Rangel-Villalobos; Mara Anaís Llamas-Covarrubias; José Francisco Muñoz-Valle
Journal: Clin Exp Med Date: 2010-06-22 Impact factor: 3.984

5. Platelet glycoprotein IIIA PIA2 polymorphism is associated with ST elevation acute myocardial infarction in young Mexican population.

Authors: David Santiago-Germán; Alfredo Leaños-Miranda; Ethel García-Latorre; Gabriela Borrayo-Sánchez; Abraham Majluf-Cruz; Irma Isordia-Salas
Journal: J Thromb Thrombolysis Date: 2012-05 Impact factor: 2.300

6. Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis.

Authors: Norma Torres-Carrillo; Nora Magdalena Torres-Carrillo; Gloria Esther Martínez-Bonilla; Mónica Vázquez-Del Mercado; Claudia Azucena Palafox-Sánchez; Edith Oregón-Romero; Ana Guilaisne Bernard-Medina; Héctor Rangel-Villalobos; José Francisco Muñoz-Valle
Journal: Clin Exp Med Date: 2009-02-24 Impact factor: 3.984